fibrinolytic TAFIa carboxypeptidase inhibitor

Ph. II candidate for pulm. embolism; discont.

from literature pharmacophore and SBDD

J. Med. Chem., Mar. 25, 2021

Servier, Croissy-sur-Seine, FR

S62798-(Servier)

The Servier thrombin activatable fibrinolysis inhibitor (TAFIa) inhibitor (S62798) is a fibrinolytic (clot degrading) agent which entered Ph. II in the EU for pulmonary embolism, but development appears to have been…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: